Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

94.02 -0.70 (-0.74%)
Official Closing Price Updated: 7:00 PM EDT, Mar 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Merck & Co

< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free Survival (EFS) Result Versus Neoadjuvant Chemotherapy Alone in High-Risk Early-Stage TNBC
From Merck & Co., Inc.
Via Business Wire
Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021
From Merck & Co., Inc.
Via Business Wire
Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
From Merck
Via Business Wire
FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)
From Merck & Co., Inc.
Via Business Wire
Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Third-Line Gastric Cancer in the US
From Merck & Co., Inc.
Via Business Wire
Merck to Hold Second-Quarter 2021 Sales and Earnings Conference Call on July 29
From Merck & Co., Inc.
Via Business Wire
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Merck Appoints Michael Klobuchar Chief Strategy Officer
From Merck & Co., Inc.
Via Business Wire
LYNPARZA® (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Persistent, Recurrent or Metastatic Cervical Cancer
From Merck & Co., Inc.
Via Business Wire
Merck Announces the Kenneth C. Frazier Award for Maternal Health Equity to Accelerate Progress Towards Improved Birth Outcomes for All
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Merck to Participate in the Guggenheim Biopharma Strategy Series
From Merck & Co., Inc.
Via Business Wire
Merck Announces the Kenneth C. Frazier Award for Maternal Health Equity to Accelerate Progress towards Improved Birth Outcomes for All
From Merck & Co., Inc.
Via Business Wire
Merck Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19
From Merck & Co., Inc.
Via Business Wire
New Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting
From Merck & Co., Inc.
Via Business Wire
LYNPARZA® (olaparib) Reduced the Risk of Invasive Disease Recurrence or Death by 42% Versus Placebo in Adjuvant Treatment of Patients With Germline BRCA Mutations and High-Risk HER2-Negative Early Breast Cancer in Phase 3 OlympiA Trial
From Merck & Co., Inc.
Via Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC)
From Merck & Co., Inc.
Via Business Wire
Merck Announces Completion of Organon & Co. Spinoff
From Merck & Co., Inc.
Via Business Wire
Merck and Sanofi’s First and Only Six-in-One Pediatric Combination Vaccine Now Available in the United States
From Merck & Co., Inc.
Via Business Wire
Merck Announces Third-Quarter 2021 Dividend
From Merck & Co., Inc.
Via Business Wire
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
The Companies Tackling A Global Health Crisis
Via FinancialNewsMedia
Merck Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) Phase 3 Pediatric Studies for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine
From Merck & Co., Inc.
Via Business Wire
Merck Named to 100 Best Corporate Citizens of 2021
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Topics Climate Change
Exposures Climate
Psychedelics Move to The Forefront of Innovative Research as the FDA Approves Large-Scale Testing
Via FinancialNewsMedia
Exposures Product Safety
Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
Merck Declares Record Date and Dividend for the Organon & Co. Spinoff
From Merck & Co., Inc.
Via Business Wire
Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program
From Merck
Via Business Wire
Merck and Eisai Receive Priority Review From FDA for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma
From Merck & Co., Inc.
Via Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.